All In Biotech

Drug Trial Radar · NCT03470922

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 714 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

714

Actual

Start

Apr 11, 2018

Primary completion

Jan 25, 2021

Study completion Dec 15, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.

Conditions

  • Melanoma

Interventions

  • RelatlimabBiological

    Specified dose on specified day

  • NivolumabBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From randomization to date of first documented tumor progression or death (up to approximately 33 months)

Locations

127 sites in 25 countries. Site status is shown where the registry gives one.

  • Local Institution - 0010

    Tucson, Arizona

  • Local Institution - 0020

    Los Angeles, California

  • Coastal Integrative Cancer Care

    San Luis Obispo, California

  • Local Institution - 0116

    Santa Barbara, California

  • Local Institution - 0012

    Washington D.C., District of Columbia

  • Local Institution - 0013

    Jacksonville, Florida

  • Local Institution - 0117

    Orlando, Florida

  • Local Institution - 0007

    Tampa, Florida

  • Local Institution - 0038

    Atlanta, Georgia

  • Local Institution - 0016

    Chicago, Illinois

  • Local Institution - 0114

    Fort Wayne, Indiana

  • Local Institution - 0077

    Baltimore, Maryland

  • Local Institution - 0120

    Baltimore, Maryland

  • Local Institution - 0014

    Boston, Massachusetts

  • Local Institution - 0134

    Boston, Massachusetts

  • Local Institution - 0015

    Ann Arbor, Michigan

  • Local Institution - 0009

    Minneapolis, Minnesota

  • Local Institution - 0011

    Rochester, Minnesota

  • Local Institution - 0018

    Charlotte, North Carolina

  • Local Institution - 0019

    Allentown, Pennsylvania

  • Local Institution - 0076

    Dallas, Texas

  • Local Institution - 0008

    Houston, Texas

  • Local Institution - 0004

    Buenos Aires, Argentina

  • Local Institution - 0003

    Buenos Aires, Argentina

  • Local Institution - 0005

    Buenos Aires, Argentina

  • Local Institution - 0135

    Buenos Aires, Distrito Federal, Argentina

  • Local Institution - 0002

    Capital Federal, Distrito Federal, Argentina

  • Local Institution - 0042

    North Sydney, New South Wales, Australia

  • Local Institution - 0043

    Waratah, New South Wales, Australia

  • Local Institution - 0041

    Greenslopes, Queensland, Australia

  • Local Institution - 0045

    Southport, Queensland, Australia

  • Local Institution - 0133

    Bedford Park, South Australia, Australia

  • Local Institution - 0044

    Murdoch, Western Australia, Australia

  • Local Institution - 0037

    Salzburg, Austria

  • Local Institution - 0035

    Vienna, Austria

  • Local Institution - 0036

    Graz, Styria, Austria

  • Local Institution - 0047

    Brussels, Belgium

  • Local Institution - 0049

    Brussels, Belgium

  • Local Institution - 0048

    Ghent, Belgium

  • Local Institution - 0059

    Rio de Janiro, Brazil

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.